BMS CA209-063: A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens
||Benjamin Levy, MD
| Time frame of study:
|Location of Study:
Beth Israel Comprehensive Cancer Center
Beth Israel Medical Center
Continuum Cancer Research Program
This is an open study that will test the effectiveness safety, and tolerability of an experimental drug called BMS-936558, which is an antibody (a type of human protein) that is being tested to see if it will allow the body’s immune system to work against tumor cells for the treatment of subjects with NSCLS, renal carcinoma (RCC) and melanoma. Subjects will receive drug every 2 weeks until disease progression or treatment discontinuation.
- Subjects with histologically- or cytologically-documented squamous cell NSCLC who present with Stage IIIB/ Stage IV disease
- At least 18 years of age
- Subjects must have experienced disease progression or recurrence after both first-line platinum doublet chemotherapy and at least one US FDA or EMA-approved subsequent line of systemic therapy.
- Subject is not pregnant or breast feeding.
Please call for more information